There are reports of a potential link between the use of Dupixent and an increased risk of cutaneous T-cell lymphoma, a rare skin lymphoma. Lawsuits have been filed over alleged cancer risks associated with Dupixent, with some studies suggesting a higher risk of this condition in users. The specifics of the litigation and the extent of the risk are not entirely clear, but patients are being informed about the potential connection.